These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 19333199)

  • 1. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
    Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
    J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.
    Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Colombo N; Fanucchi A; Chiudinelli F; Lapresa M; Maria Ferrero A
    Gynecol Oncol; 2005 Jul; 98(1):118-23. PubMed ID: 15913740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
    Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D
    Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
    van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
    Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review.
    Obermair A; Handisurya A; Kaider A; Sevelda P; Kölbl H; Gitsch G
    Cancer; 1998 Aug; 83(4):726-31. PubMed ID: 9708937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Barnes MN
    Gynecol Oncol; 2008 Feb; 108(2):336-41. PubMed ID: 18006047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
    Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
    Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
    Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
    Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
    Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA
    Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinum-based chemotherapy.
    Pongsanon K; Benjapibal M; Ruengkhachorn I
    Asian Pac J Cancer Prev; 2011; 12(1):131-6. PubMed ID: 21517245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
    Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer.
    Ferrero A; Zola P; Mazzola S; Fuso L; Sarotto I; Ravarino N; Spanu PG; Jacomuzzi ME; Carus AP; Sismondi P
    Gynecol Oncol; 2004 Nov; 95(2):323-9. PubMed ID: 15491752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A retrospective study of advanced ovarian cancer in our ward].
    Baba T; Utsunomiya Y; Tamai A; Ueda M; Goto M; Nonogaki T
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2071-5. PubMed ID: 14712767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.